TNIK Kinase Inhibitor Structures for Selective Wnt Pathway Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for TNIK kinase, which is implicated in various biological processes including carcinogenesis and cancer metastasis, and there is a need for specific inhibitors that can target this kinase to treat diseases such as colorectal cancer and cognitive disabilities.
Innovation Solution
Development of compounds with specific structures, such as Formula A, which can inhibit TNIK kinase activity by contacting it with molecules that act as inhibitors, including derivatives, salts, stereoisomers, or solvates, to block the Wnt pathway and other related pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of diseases is provided, but effective inhibition of TNIK kinase activity is not achieved
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (Formula A and variations) that are optimized to bind to and inhibit TNIK kinase. The chemical parameters of the inhibitor molecules are systematically modified to achieve selective and effective inhibition of TNIK kinase activity, thereby resolving the contradiction between general therapy effectiveness and specific kinase targeting capability
2Object-affected harmful factors
If general kinase inhibitors are used, then broad kinase activity is inhibited, but specific TNIK kinase inhibition is not achieved
Solution Approach 1:
The patent applies local quality by designing inhibitor molecules with specific structural features (substituents at defined positions in Formula A) that create localized interaction zones with TNIK kinase. This enables the inhibitor to selectively bind to TNIK kinase through specific local molecular interactions, achieving high selectivity while effectively inhibiting the target kinase's harmful activity
3Productivity
If no specific TNIK inhibitor is available, then research and treatment can proceed, but therapeutic benefits for TNIK-related diseases cannot be realized
Solution Approach 1:
The patent applies preliminary action by providing a series of pre-developed TNIK kinase inhibitors with characterized structures and activities. These pre-developed compounds enable researchers to immediately conduct studies on TNIK-related diseases without needing to develop inhibitors from scratch, while also providing ready-to-use therapeutic agents that can deliver reliable therapeutic benefits for TNIK-related conditions
Data Source
AI summary
A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center,wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.